Disease landscape

Chronic Myeloid Leukemia (CML) clinical trials

Get alerts when Chronic Myeloid Leukemia (CML) trials change

125 active trials 64 recruiting 6 Phase 3 80 sponsors 20 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-05

What changed in the last 30 days

2026-09-04
Primary completion pushed: 2026-06-30 → 2027-06-30
Completion pushed: 2027-12-31 → 2028-06-30
NCT03459534 A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure… · Il-Yang Pharm. Co., Ltd. · Phase 3
2026-09-04
Primary completion pushed: 2026-09-30 → 2027-07-15
Enrollment closed, study ongoing
Completion pushed: 2026-12-31 → 2027-12-31
NCT06665412 Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML · Il-Yang Pharm. Co., Ltd.
2026-08-18
Primary completion pushed: 2026-02-01 → 2026-12-24
Completion pushed: 2026-06-30 → 2026-12-30
NCT06001385 HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced… · Center for International Blood and Marrow Transplant Research · Phase 2
2026-08-19
Primary completion pushed: 2026-01-31 → 2026-05-31
Trial completed
Completion pushed: 2026-01-31 → 2026-05-31
NCT05701215 Venetoclax After TKI to Target Persisting Stem Cells in CML · Thomas Ernst, PD Dr. med. · Phase 2
2026-08-08
Primary completion pushed: 2026-08-31 → 2030-08-31
Completion pushed: 2026-08-31 → 2030-08-31
NCT05092451 Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in… · M.D. Anderson Cancer Center · Phase 1/2
2026-08-09
Sponsor changed: Terns, Inc. → Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT06163430 A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and… · Terns, Inc. · Phase 1/2
2026-09-02
Recruitment resumed after suspension
NCT05322850 Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell… · University of Florida · Phase 1/2
2026-08-27
Trial status changed: Suspended → Active, Not Recruiting
NCT07166419 Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the… · Ohio State University Comprehensive Cancer Center · Phase 1
2026-08-08
Recruitment opened
NCT07269470 Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With… · M.D. Anderson Cancer Center · Phase 2
2026-08-18
Recruitment opened
NCT07302776 TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT · Stanford University · Phase 1
2026-09-04
Completion pushed: 2025-06-30 → 2027-12-31
NCT03722420 Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With… · Il-Yang Pharm. Co., Ltd. · Phase 3
2026-08-19
Primary completion moved earlier: 2027-12 → 2027-03
NCT03906292 Frontline Asciminib Combination in Chronic Phase CML · University of Jena · Phase 2
2026-08-09
Trial status changed: Active, Not Recruiting → Unknown
NCT02061800 CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell… · Diane George · Phase 1/2

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-09-04 NCT07804901 Asciminib Frontline Risk Adapted Prof. Dr. med. Andreas Hochhaus new Phase 2
2026-08-11 NCT07758218 Allogeneic iNKT Cell Therapy (agenT-797) After SCT University of Wisconsin, Madison new Phase 1
2026-07-31 NCT07740603 Study of CD38 and CD56 in Chronic Myeloid Leukemia Sohag University new
2026-06-16 NCT07651878 Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment Mendus new Phase 1
2026-06-11 NCT07640750 Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second… Gruppo Italiano Malattie EMatologiche dell'Adulto new
2026-06-10 NCT07638007 Impact of Targeted Therapy on Cancer-Related Cognitive Impairment University of Rochester NCORP Research Base new

Active trials by phase

Early Phase 1
2
Phase 1
25
Phase 1/2
9
Phase 2
45
Phase 3
6
Phase 4
1
Not charted: 37 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 125

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT05367765 A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients… Jiangsu Hansoh Pharmaceutical Co., Ltd. Not Yet Recruiting 2022-05-10
Phase 3
NCT03459534 A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure… Il-Yang Pharm. Co., Ltd. Recruiting 2026-09-03
NCT06423911 Study of Olverembatinib (HQP1351) in Patients With CP-CML Ascentage Pharma Group Inc. Recruiting 2025-06-03
NCT03722420 Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With… Il-Yang Pharm. Co., Ltd. Active, Not Recruiting 2026-09-03
NCT04971226 A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+… Novartis Pharmaceuticals Active, Not Recruiting 2026-08-28
NCT05456191 A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib… Novartis Pharmaceuticals Active, Not Recruiting 2026-08-26
NCT05753384 Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and… Poitiers University Hospital Active, Not Recruiting 2026-04-27
Phase 2
NCT07269470 Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With… M.D. Anderson Cancer Center Recruiting 2026-08-25
NCT06236724 Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly… M.D. Anderson Cancer Center Recruiting 2026-08-14
NCT06013423 Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in… Fred Hutchinson Cancer Center Recruiting 2026-07-22
NCT02889003 Second STOP After Pioglitazone Priming in CML Patients Versailles Hospital Recruiting 2026-07-06
NCT06802315 Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen… University of Illinois at Chicago Recruiting 2026-06-26
NCT05800210 Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in… University of Florida Recruiting 2026-06-04
NCT04195633 Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for… Fred Hutchinson Cancer Center Recruiting 2026-05-29
NCT06817720 Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in… M.D. Anderson Cancer Center Recruiting 2026-05-20
NCT06514534 Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are… Novartis Pharmaceuticals Recruiting 2026-04-21
NCT06368414 A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia Korean Society of Hematology Recruiting 2026-04-02
NCT06859424 A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based… Center for International Blood and Marrow Transplant Research Recruiting 2026-03-17
NCT06059391 CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of… City of Hope Medical Center Recruiting 2026-03-10
NCT07238712 Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With… St. Petersburg State Pavlov Medical University Recruiting 2025-11-20
NCT05031897 Two Step Haplo With Radiation Conditioning Thomas Jefferson University Recruiting 2025-10-30
NCT05884333 Cord Blood Transplant in Adults With Blood Cancers Memorial Sloan Kettering Cancer Center Recruiting 2025-09-08
NCT06409936 PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML Gruppo Italiano Malattie EMatologiche dell'Adulto Recruiting 2025-07-08
NCT06355583 Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial Imperial College London Recruiting 2025-04-17
NCT06453902 TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients Shenzhen TargetRx Co., Ltd. Recruiting 2025-02-21
See all 125 active Chronic Myeloid Leukemia (CML) trials with filters →

Top sponsors by active trials in this area

Novartis Pharmaceuticals (7) · M.D. Anderson Cancer Center (6) · City of Hope Medical Center (4) · Poitiers University Hospital (4) · Assiut University (3) · Baylor College of Medicine (3) · Center for International Blood and Marrow Transplant Research (3) · Fred Hutchinson Cancer Center (3) · Gruppo Italiano Malattie EMatologiche dell'Adulto (3) · Il-Yang Pharm. Co., Ltd. (3)

Get alerts when Chronic Myeloid Leukemia (CML) trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free